Key result
Three patients developed self-limited and reversible delayed profound thrombocytopenia five days following abciximab therapy, without serious bleeding complications.
Case Report (n=3)
Abciximab therapy can cause delayed profound thrombocytopenia up to five days post-administration, which may be self-limited and reversible without serious bleeding.
May warrant delayed platelet monitoring after abciximab; case reports leave open true incidence and management.
Inhibitors of glycoprotein (GP) IIb/IIIa are currently approved for the treatment of acute coronary syndromes and during performance of percutaneous coronary interventions (PCIs). More than 500 000 patients annually undergo PCIs in the USA alone. Of these, 35% are receiving GPIIb/IIIa inhibitors. Currently, three different intravenous GPIIb/IIIa inhibitors are commercially available. Profound thrombocytopenia occurs almost exclusively with abciximab. Usually thrombocytopenia develops within 24 hours following abciximab administration. This paper describes three patients who developed delayed profound thrombocytopenia, occurring five days following abciximab therapy. These cases of thrombocytopenia were self-limited and reversible. Absence of serious bleeding complications was noted. The pathophysiology, differential diagnosis, natural history and management of the coronary patients with abciximab-induced thrombocytopenia are discussed.
No takes yet. Share an insight, caveat, or question.
Kaluski et al. (2001) conducted a case report in Delayed profound thrombocytopenia (n=3). Abciximab was evaluated on Delayed profound thrombocytopenia. Three patients developed self-limited and reversible delayed profound thrombocytopenia five days following abciximab therapy, without serious bleeding complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: